文献速递银屑病与炎症性皮肤病皮肤感染

阿达木单抗用于合并乙肝或丙肝的银屑病患者安全可行:37例多中心队列研究及文献回顾

Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-02-21

该多中心队列研究评估了阿达木单抗在37例合并慢性HBV或HCV感染的银屑病患者中的长期安全性,其中HBV感染17例、HCV感染20例。患者治疗反应良好,平均随访27个月(HBV)和40个月(HCV)期间未见病毒再激活;8例HCV患者纤维化评分从治疗前均值5.83略降至治疗后5.65。结论认为阿达木单抗似安全,但仍需大规模前瞻性研究提供更多信息。

要点

  • 合并慢性HBV或HCV的银屑病患者使用阿达木单抗未见病毒再激活。
  • HBV组平均随访27个月,HCV组平均随访40个月,治疗反应良好。
  • 8例HCV患者纤维化评分从均值5.83略降至5.65。

核心结论

  • 阿达木单抗似对合并HBV或HCV感染的严重银屑病患者安全。
  • 仍需大规模前瞻性研究评估抗TNF治疗对肝功能的影响及监测方案。

研究设计与样本

  • 多中心队列研究,纳入意大利四个转诊中心的37例连续银屑病患者。
  • 其中慢性HBV感染17例,慢性HCV感染20例,均接受阿达木单抗治疗。
  • 治疗前及随访结束时评估,部分患者进行病毒载量和影像学检查(超声、Fibroscan)。

主要发现

  • 患者治疗反应良好,HBV组平均随访27个月、HCV组平均随访40个月均无病毒再激活。
  • 8例HCV患者纤维化评分治疗前均值5.83,治疗后均值5.65,略有下降。

临床怎么用

  • 对合并慢性HBV或HCV的银屑病患者,阿达木单抗可作为治疗选择之一。
  • 治疗期间需关注病毒载量和肝功能,但具体监测方案原文未明确。

局限性

  • 样本量较小(37例),随访时间有限。
  • 仅部分患者进行了病毒载量和影像学检查。
  • 需大规模前瞻性研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Little data are available about the safety of TNF-α inhibitors in patients with HCV and HBV infection. In particular, data concerning the use of adalimumab in patients with psoriasis and concomitant viral hepatitis are lacking and little is known about the drug's real safety in this context. OBJECTIVE: To assess the long-term safety of adalimumab in a group of 17 consecutive psoriatic patients affected by chronic HBV infection and 20 consecutive psoriatic patients affected by chronic HCV infection. METHODS: Thirty-seven consecutive patients with psoriasis and concomitant HBV or HCV infection being treated with adalimumab at four Italian referral centres (Modena, Padova, Verona and Turin) were assessed before the treatment and at the end of follow-up. Viral load and radiological studies (echography, Fibroscan) were also carried out in some of the patients. RESULTS: The patients responded well to treatment and did not show any HBV or HCV reactivation in a mean follow-up period of 27 and 40 months, respectively. The fibrosis score in eight HCV patients showed a slight reduction: pretreatment mean value 5.83 and post-treatment mean value 5.65. CONCLUSION: The use of adalimumab seems to be safe in patients with severe psoriasis and HBV or HCV infection. Nevertheless, large-scale prospective studies will be able to provide vital information on the impact of anti-TNF treatment on hepatic function in patients with psoriasis and concomitant chronic HCV or HBV infection and appropriate monitoring scheduling.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Piaserico S, Dapavo P, Conti A, et al. Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. J Eur Acad Dermatol Venereol. 2017. PMID: 28146345. doi:10.1111/jdv.14146

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。